Start building new facility Polyganics
Wednesday 4 March 2020
- Life Cooperative
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced the ground-breaking of a new facility at Campus Groningen, location Zernike Campus. On Tuesday 3 March 2020 the official launch of the new building on Zernike Campus was done by Rudy Mareel (Polyganics), Jan Disbergen (Polyganics), Saskia van Ham (municipality of Groningen) and Edward van der Meer (Campus Groningen). Polyganics aims to move into its new facility, which will house its headquarters, state-of-the-art research laboratories and expanded manufacturing and packaging facilities, in 2021.
With the continued increase in demand for its ENT (Ear, Nose, Throat) and PNR (Peripheral Nerve Repair) portfolio, together with the strong commercial launch of LIQOSEAL® and a highly promising growth outlook for various pipeline products, the move to a larger facility is essential for Polyganics. The purpose-built facility will provide the space to ensure that the company can continue to develop and deliver a reliable supply of bioresorbable medical devices to its customers and remain at the forefront of research and manufacturing excellence.
Perfect match
Paul de Rook, vice mayor of the city Groningen commented: "As an innovative medical technology company with customers world-wide, Polyganics is an excellent example of a Groningen University spin out with a thriving economic growth potential. I am pleased that a RIG subsidy (Regional Investment Aid Groningen) helped secure this investment, thereby securing the company’s long term sustainable future in Groningen. It will not only create and safeguard a significant number of high quality jobs but will also support the local economy through cooperation with various regional companies."
Edward van der Meer, Director Campus Groningen: "We are delighted to welcome Polyganics at Campus Groningen, location Zernike; the Northern Netherland’s driver of innovation. More than 4000 researchers, employees and a few hundred entrepreneurs work here on innovative solutions which are of importance in the future. Polyganics is a perfect fit within the focus of Campus Groningen on energy, chemistry, life sciences and big data. In addition, Polyganics can benefit from the strong connections from of Campus Groningen and her stakeholders: the University Medical Center Groningen (UMCG), the University of Groningen, the Hanze University of Applied Sciences and of multiple Life-Science oriented firms located at this campus. Without doubt, Polyganics will provide a significant contribution to the exciting synergies that exist between residents of this campus."
Rudy Mareel, CEO of Polyganics commented: "We are proud of our continuing successes in R&D, product development, manufacturing and commercialization, which is reflected in the need for increased capacity, that cannot be achieved at the current location. We are grateful to our partners, especially to the city and province of Groningen, to support this expansion. Ground-breaking of the new facility is another major milestone in our ultimate goal to transform patient recovery after surgical procedures."
“We have a strong chemical cluster here at Campus Groningen together with a.o. Polyvation, Innolab Chemistry, MercachemSyncom, Cliq Swiss BV, BioBTX and Innovation Center Avebe, among others. Polyganics naturally fits in perfectly with this ”.
Focus areas
Life CooperativeLatest news
-
Thursday 5 November 2020
Start-up Reperio developing diagnostic technology for glau..
-
Monday 21 September 2020
Campus ecosystem invests in SG Papertronics
-
Wednesday 16 September 2020
First patients treated in First-in-Human Trial for Polygan..
-
Tuesday 15 September 2020
InnoCore Pharmaceuticals to develop long-acting injectable..
-
Wednesday 9 September 2020
Agreement signed for new Innovation Center Chemistry and E..
-
Wednesday 2 September 2020
Campus Community Fund invests 500 million euros in Campus ..
-
Thursday 6 August 2020
Pharma Connect Capital invests in Hercules Pharmaceuticals..
-
Tuesday 4 August 2020
OFINEXT 100% part of the Ofichem Group
-
Friday 26 June 2020
On the way to 'one size fits all' tracer
-
Wednesday 10 June 2020
QPS hopeful about drug for corona patients

English
Nederlands